Dr. David P. Warshal

Claim this profile

Cooper Hospital University Medical Center

Studies Ovarian Cancer
Studies Ovarian Tumors
13 reported clinical trials
30 drugs studied

Area of expertise

1Ovarian Cancer
David P. Warshal has run 6 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRCA1 positive
2Ovarian Tumors
David P. Warshal has run 5 trials for Ovarian Tumors. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
Cooper Hospital University Medical Center
Image of trial facility.
MD Anderson Cancer Center At Cooper-Voorhees

Clinical Trials David P. Warshal is currently running

Image of trial facility.

Letrozole +/- Chemotherapy

for Ovarian Cancer

This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
Recruiting2 awards Phase 318 criteria
Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Recruiting1 award Phase 2 & 3

More about David P. Warshal

Clinical Trial Related1 year of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments David P. Warshal has experience with
  • Carboplatin
  • Paclitaxel
  • Pembrolizumab
  • GEN-1
  • AGEN2034
  • AGEN1884

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David P. Warshal specialize in?
David P. Warshal focuses on Ovarian Cancer and Ovarian Tumors. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is David P. Warshal currently recruiting for clinical trials?
Yes, David P. Warshal is currently recruiting for 3 clinical trials in Camden New Jersey. If you're interested in participating, you should apply.
Are there any treatments that David P. Warshal has studied deeply?
Yes, David P. Warshal has studied treatments such as Carboplatin, Paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with David P. Warshal?
Apply for one of the trials that David P. Warshal is conducting.
What is the office address of David P. Warshal?
The office of David P. Warshal is located at: Cooper Hospital University Medical Center, Camden, New Jersey 08103 United States. This is the address for their practice at the Cooper Hospital University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.